Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Comer SD, Cahill CM.

Neurosci Biobehav Rev. 2018 Dec 5. pii: S0149-7634(18)30207-0. doi: 10.1016/j.neubiorev.2018.12.005. [Epub ahead of print] Review.

PMID:
30528374
2.

How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies.

Neale J, Brown C, Campbell ANC, Jones JD, Metz VE, Strang J, Comer SD.

Addiction. 2018 Nov 26. doi: 10.1111/add.14510. [Epub ahead of print]

PMID:
30476356
3.

Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M.

Addict Biol. 2018 Oct 31. doi: 10.1111/adb.12664. [Epub ahead of print]

PMID:
30378231
4.

The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety.

Jones JD, Bisaga A, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Madera G, Doernberg M, Comer SD.

J Psychoactive Drugs. 2018 Nov-Dec;50(5):390-401. doi: 10.1080/02791072.2018.1508789. Epub 2018 Sep 11.

PMID:
30204554
5.

Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.

Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, Foltin RW, Levin FR.

Addict Biol. 2018 Apr 16. doi: 10.1111/adb.12621. [Epub ahead of print]

PMID:
29659126
6.

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.

Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M.

Neuropsychopharmacology. 2018 Sep;43(10):2046-2055. doi: 10.1038/s41386-018-0011-2. Epub 2018 Feb 5.

PMID:
29463913
7.

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, Navarro HA, Langston TL, Runyon SP, Winston S, Pravetoni M, Pentel PR.

PLoS One. 2017 Dec 1;12(12):e0184876. doi: 10.1371/journal.pone.0184876. eCollection 2017.

8.

Chronic pain and opioid abuse: Factors associated with health-related quality of life.

Jones JD, Vogelman JS, Luba R, Mumtaz M, Comer SD.

Am J Addict. 2017 Dec;26(8):815-821. doi: 10.1111/ajad.12637. Epub 2017 Nov 21.

9.

Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.

Jones JD, Comer SD, Metz VE, Manubay JM, Mogali S, Ciccocioppo R, Martinez S, Mumtaz M, Bisaga A.

Pharmacol Biochem Behav. 2017 Dec;163:90-100. doi: 10.1016/j.pbb.2017.10.002. Epub 2017 Oct 8.

10.

Glial and neuroinflammatory targets for treating substance use disorders.

Bachtell RK, Jones JD, Heinzerling KG, Beardsley PM, Comer SD.

Drug Alcohol Depend. 2017 Nov 1;180:156-170. doi: 10.1016/j.drugalcdep.2017.08.003. Epub 2017 Aug 31. Review.

11.

Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.

Jones JD, Manubay JM, Mogali S, Metz VE, Madera G, Martinez S, Mumtaz M, Comer SD.

Drug Alcohol Depend. 2017 Oct 1;179:362-369. doi: 10.1016/j.drugalcdep.2017.06.033. Epub 2017 Jul 26.

PMID:
28844013
12.

Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers.

Cooper ZD, Johnson KW, Vosburg SK, Sullivan MA, Manubay J, Martinez D, Jones JD, Saccone PA, Comer SD.

Drug Alcohol Depend. 2017 Sep 1;178:340-347. doi: 10.1016/j.drugalcdep.2017.04.029. Epub 2017 Jun 17.

PMID:
28688296
13.

Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S.

JAMA Psychiatry. 2017 Sep 1;74(9):894-902. doi: 10.1001/jamapsychiatry.2017.1874.

14.

Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Smith SM, Jones JK, Katz NP, Roland CL, Setnik B, Trudeau JJ, Wright S, Burke LB, Comer SD, Dart RC, Dionne R, Haddox JD, Jaffe JH, Kopecky EA, Martell BA, Montoya ID, Stanton M, Wasan AD, Turk DC, Dworkin RH.

J Pain. 2017 Nov;18(11):1287-1294. doi: 10.1016/j.jpain.2017.03.015. Epub 2017 May 4.

15.

Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.

Metz VE, Jones JD, Manubay J, Sullivan MA, Mogali S, Segoshi A, Madera G, Johnson KW, Comer SD.

Neuropsychopharmacology. 2017 Aug;42(9):1825-1832. doi: 10.1038/npp.2017.70. Epub 2017 Apr 10.

16.

No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone.

Jones JD, Campbell A, Metz VE, Comer SD.

Addict Behav. 2017 Aug;71:104-106. doi: 10.1016/j.addbeh.2017.03.008. Epub 2017 Mar 9.

17.

Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.

Neelakantan H, Holliday ED, Fox RG, Stutz SJ, Comer SD, Haney M, Anastasio NC, Moeller FG, Cunningham KA.

ACS Chem Neurosci. 2017 May 17;8(5):1065-1073. doi: 10.1021/acschemneuro.6b00413. Epub 2017 Feb 13.

18.

Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder.

Metz VE, Sullivan MA, Jones JD, Evans E, Luba R, Vogelman J, Comer SD.

J Psychoactive Drugs. 2017 Jan-Mar;49(1):59-68. doi: 10.1080/02791072.2016.1259518. Epub 2016 Dec 5.

19.

Can Naloxone Be Used to Treat Synthetic Cannabinoid Overdose?

Jones JD, Nolan ML, Daver R, Comer SD, Paone D.

Biol Psychiatry. 2017 Apr 1;81(7):e51-e52. doi: 10.1016/j.biopsych.2016.08.013. Epub 2016 Aug 18. No abstract available.

20.

Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M.

Psychopharmacology (Berl). 2016 Jul;233(13):2469-78. doi: 10.1007/s00213-016-4298-6. Epub 2016 Apr 16.

21.

The effects of heroin administration and drug cues on impulsivity.

Jones JD, Vadhan NP, Luba RR, Comer SD.

J Clin Exp Neuropsychol. 2016 Aug;38(6):709-20. doi: 10.1080/13803395.2016.1156652. Epub 2016 Apr 10.

22.

Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Jones JD, Luba RR, Vogelman JL, Comer SD.

Am J Addict. 2016 Jan;25(1):41-8. doi: 10.1111/ajad.12316. Epub 2015 Dec 21.

23.

The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone among nondependent opioid users.

Jones JD, Sullivan MA, Manubay JM, Mogali S, Metz VE, Ciccocioppo R, Comer SD.

Physiol Behav. 2016 May 15;159:33-9. doi: 10.1016/j.physbeh.2015.10.006. Epub 2015 Oct 9.

24.

Inflammatory Pain Promotes Increased Opioid Self-Administration: Role of Dysregulated Ventral Tegmental Area μ Opioid Receptors.

Hipólito L, Wilson-Poe A, Campos-Jurado Y, Zhong E, Gonzalez-Romero J, Virag L, Whittington R, Comer SD, Carlton SM, Walker BM, Bruchas MR, Morón JA.

J Neurosci. 2015 Sep 2;35(35):12217-31. doi: 10.1523/JNEUROSCI.1053-15.2015.

25.

Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users.

Jones JD, Atchison JJ, Madera G, Metz VE, Comer SD.

Drug Alcohol Depend. 2015 Aug 1;153:201-6. doi: 10.1016/j.drugalcdep.2015.05.021. Epub 2015 May 27.

26.

The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD.

Addict Biol. 2016 Jul;21(4):895-903. doi: 10.1111/adb.12261. Epub 2015 May 14.

27.

A review of pharmacogenetic studies of substance-related disorders.

Jones JD, Comer SD.

Drug Alcohol Depend. 2015 Jul 1;152:1-14. doi: 10.1016/j.drugalcdep.2015.03.003. Epub 2015 Mar 18. Review.

28.

The pharmacogenetics of alcohol use disorder.

Jones JD, Comer SD, Kranzler HR.

Alcohol Clin Exp Res. 2015 Mar;39(3):391-402. doi: 10.1111/acer.12643. Epub 2015 Feb 19. Review.

29.

Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users.

Askalsky P, Kalapatapu RK, Foltin RW, Comer SD.

Am J Drug Alcohol Abuse. 2015 Mar;41(2):161-5. doi: 10.3109/00952990.2014.966197. Epub 2014 Oct 16.

30.

Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Greenwald MK, Comer SD, Fiellin DA.

Drug Alcohol Depend. 2014 Nov 1;144:1-11. doi: 10.1016/j.drugalcdep.2014.07.035. Epub 2014 Aug 19. Review.

31.

Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Jones JD, Sullivan MA, Vosburg SK, Manubay JM, Mogali S, Metz V, Comer SD.

Addict Biol. 2015 Jul;20(4):784-98. doi: 10.1111/adb.12163. Epub 2014 Jul 25.

32.

Characteristics and quality of life of opioid-dependent pregnant women in Austria.

Metz VE, Comer SD, Wuerzl J, Pribasnig A, Fischer G.

Arch Womens Ment Health. 2014 Dec;17(6):529-39. doi: 10.1007/s00737-014-0443-6. Epub 2014 Jul 15.

33.

The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

Jones JD, Madera G, Comer SD.

Pharmacol Biochem Behav. 2014 Jul;122:299-306. doi: 10.1016/j.pbb.2014.04.012. Epub 2014 May 2.

34.

Abuse liability measures for use in analgesic clinical trials in patients with pain: IMMPACT recommendations.

O'Connor AB, Turk DC, Dworkin RH, Katz NP, Colucci R, Haythornthwaite JA, Klein M, O'Brien C, Posner K, Rappaport BA, Reisfield G, Adams EH, Balster RL, Bigelow GE, Burke LB, Comer SD, Cone E, Cowan P, Denisco RA, Farrar JT, Foltin RW, Haddox JD, Hertz S, Jay GW, Junor R, Kopecky EA, Leiderman DB, McDermott MP, Palmer PP, Raja SN, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Smith SM, Sokolowska M, Stauffer JW, Walsh SL, Zacny JP.

Pain. 2013 Nov;154(11):2324-34. doi: 10.1016/j.pain.2013.06.035. Review.

PMID:
24148704
35.

Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection.

Roux P, Fugon L, Jones JD, Comer SD.

Am J Addict. 2013 Nov-Dec;22(6):613-8. doi: 10.1111/j.1521-0391.2013.12058.x. Epub 2013 Jun 6.

36.

Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use.

Gudin JA, Mogali S, Jones JD, Comer SD.

Postgrad Med. 2013 Jul;125(4):115-30. doi: 10.3810/pgm.2013.07.2684. Review.

37.

Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Comer SD, Metz VE, Cooper ZD, Kowalczyk WJ, Jones JD, Sullivan MA, Manubay JM, Vosburg SK, Smith ME, Peyser D, Saccone PA.

Behav Pharmacol. 2013 Sep;24(5-6):504-16. doi: 10.1097/FBP.0b013e328363d1c4.

38.

A review of human drug self-administration procedures.

Jones JD, Comer SD.

Behav Pharmacol. 2013 Sep;24(5-6):384-95. doi: 10.1097/FBP.0b013e3283641c3d. Review.

39.

Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

Sullivan MA, Bisaga A, Mariani JJ, Glass A, Levin FR, Comer SD, Nunes EV.

Drug Alcohol Depend. 2013 Nov 1;133(1):80-5. doi: 10.1016/j.drugalcdep.2013.05.030. Epub 2013 Jul 1.

40.

Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.

Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH; Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership.

Pain. 2013 Nov;154(11):2287-96. doi: 10.1016/j.pain.2013.05.053. Epub 2013 Jun 20. Review.

41.

Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users.

Jones JD, Roux P, Stancliff S, Matthews W, Comer SD.

Int J Drug Policy. 2014 Jan;25(1):166-70. doi: 10.1016/j.drugpo.2013.05.006. Epub 2013 Jun 15.

42.

Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.

Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW.

Neuropsychopharmacology. 2013 Nov;38(12):2427-38. doi: 10.1038/npp.2013.143. Epub 2013 Jun 5.

43.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD.

Pain. 2013 Aug;154(8):1442-8. doi: 10.1016/j.pain.2013.05.004. Epub 2013 May 7.

44.

Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.

Cooper ZD, Comer SD, Haney M.

Neuropsychopharmacology. 2013 Sep;38(10):1984-92. doi: 10.1038/npp.2013.97. Epub 2013 Apr 22.

45.

Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW.

Neuropsychopharmacology. 2013 Jul;38(8):1557-65. doi: 10.1038/npp.2013.54. Epub 2013 Feb 26.

46.

Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone.

Jones JD, Speer T, Comer SD, Ross S, Rotrosen J, Reid MS.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):86-91. doi: 10.3109/00952990.2012.762372.

47.

A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

Vosburg SK, Jones JD, Manubay JM, Ashworth JB, Shapiro DY, Comer SD.

Addiction. 2013 Jun;108(6):1095-106. doi: 10.1111/add.12114. Epub 2013 Mar 13.

48.

Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations.

Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, Farrar JT, Haddox JD, Haythornthwaite JA, Hertz S, Jay GW, Johanson CE, Junor R, Katz NP, Klein M, Kopecky EA, Leiderman DB, McDermott MP, O'Brien C, O'Connor AB, Palmer PP, Raja SN, Rappaport BA, Rauschkolb C, Rowbotham MC, Sampaio C, Setnik B, Sokolowska M, Stauffer JW, Walsh SL.

Pain. 2012 Dec;153(12):2315-24. doi: 10.1016/j.pain.2012.07.035. Epub 2012 Sep 19.

49.

Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status.

Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, Foltin RW.

Biol Psychiatry. 2013 Feb 1;73(3):242-8. doi: 10.1016/j.biopsych.2012.07.028. Epub 2012 Aug 29.

50.

Supplemental Content

Loading ...
Support Center